Invivyd Reports VYD2311 Meets Primary Safety Endpoints In Phase 3 Trial

Invivyd (IVVD) reported that its COVID-19 monoclonal antibody VYD2311 met primary safety endpoints in the Phase 3 LIBERTY study, showing favorable safety and tolerability compared to an mRNA vaccine. The study enrolled 210 healthy adults, with 56.5% of VYD2311 recipients experiencing adverse events versus 91.4% for the vaccine. The company plans to use the data to support a BLA submission to the FDA. IVVD stock closed at $0.95, up 1.69%, and is trading at $0.99 in pre-market.

Original reporting
Published Sep 29, 2026, 11:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$IVVD
Bullish
high confidence
Mentioned
$IVVD
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$IVVDBullishMed
01

Why it matters

The trial's safety profile is favorable, supporting the upcoming BLA filing under accelerated approval, which could materially affect the stock price.

02

Market read

First‑report Phase 3 safety data for a COVID‑19 therapeutic, likely to influence IVVD's valuation ahead of regulatory filing.

03

What to watch

Potential competition from updated mRNA vaccines and the need for efficacy data beyond safety.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Invivyd is a micro‑cap biotech focused on COVID‑19 monoclonal antibodies. The LIBERTY trial compared its candidate VYD2311 to an mRNA vaccine in healthy adults.

Company-level read

Ticker impact

$IVVDBullishHigh confidence
Context

Invivyd reported Phase 3 LIBERTY trial data showing VYD2311 met primary safety endpoints and had lower adverse events than an mRNA vaccine.

Expected impact

likely upward pressure as the market prices in the favorable trial results and upcoming BLA submission.

Evidence & confidence

Phase 3 safety success is material for a biotech and often triggers price appreciation, especially for a micro‑cap with pending regulatory filing.

Market effects

Strengthens the COVID‑19 prophylactic antibody segment and may benefit peers developing similar biologics.

US biotech sector could see modest gains as investors reassess pipeline prospects.

Limited to biotech investors; no broad market impact.

Counterpoint

If the antibody fails to demonstrate efficacy in later studies, the current safety win may be insufficient for a sustained rally.

Key entities

  • Invivyd, Inc.

    Biotech developer of VYD2311.

  • VYD2311

    Investigational COVID‑19 monoclonal antibody.

Related articles

$IVVDMed

Invivyd Posts Wider Loss In Q3 As Operating Expenses Rise

Invivyd, Inc. (IVVD) reported a wider Q3 net loss of $33.47 million, up from $10.47 million YoY, due to higher operating expenses. Revenue rose 18% to $15.45 million. The company provided updates on its pipeline, including VYD2311 for COVID-19 and VMS063 for measles, and announced leadership changes. Cash reserves totaled $126.40 million.

$IVVDHigh

Invivyd Reports Third Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights • DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communic

$IVVDMedAI 8/10

Invivyd presents preclinical data on measles antibody candidate

Invivyd (NASDAQ:IVVD) presented preclinical data for its measles antibody candidate VMS063 at IDWeek 2026, showing antiviral activity against measles virus variants. The company plans to scale up manufacturing for clinical development in 2027. There are currently no FDA-approved treatments for measles, with U.S. cases nearly double in 2026 compared to 2025, according to Invivyd.

$IVVDLow

Invivyd, Inc. (IVVD) Unveils Preclinical Data for Measles mAb VMS063

Invivyd, Inc. (IVVD) presented preclinical data for VMS063, a novel monoclonal antibody for measles, showing in vitro activity against contemporary virus variants. The company is scaling up production for clinical development in 2027. There are currently no FDA-approved treatments for measles, and the U.S. is experiencing a surge in cases.

$IVVDLowAI 8/10

More than 9 million U.S. children are estimated to lack measles protection. Lab tests found an antibody could fight measles.

Invivyd (Nasdaq: IVVD) presented preclinical data for VMS063, a monoclonal antibody candidate for measles treatment and prevention. VMS063 showed potent in vitro activity against measles virus variants. Invivyd plans to scale up production for clinical development in 2027. The U.S. is experiencing a record number of measles cases in 2026, with over 9 million children unprotected.